Skip to main
DRTS
DRTS logo

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has recently achieved a significant operational milestone by securing a radioactive material license in New Hampshire and completing the first phase of its commercial-scale manufacturing facility, positioning the company to begin U.S. manufacturing of its Alpha DaRT technology in 2026. The company's strong cash position indicates financial stability and potential for future growth as it seeks to address unmet needs in oncology with its innovative treatment approach. Although the reported net loss was slightly higher than anticipated, the strategic advancements in manufacturing and regulatory approvals suggest a positive trajectory for the company as it prepares to expand its market presence.

Bears say

Alpha Tau Medical reported a net loss of $11.7 million for the third quarter of 2025, highlighting significant financial challenges. The company faces considerable risks including the potential failure of its Alpha DaRT technology in clinical trials and the ongoing uncertainty surrounding its ability to secure U.S. regulatory approval. Additionally, there are concerns regarding the commercial viability of Alpha DaRT due to market size, competitive pressures, and the risk of shareholder dilution, which contribute to a negative outlook on the stock's performance.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.